2,226 results match your criteria Angioimmunoblastic Lymphoma


Multiple mutations at exon 2 of RHOA detected in plasma from patients with peripheral T-cell lymphoma.

Blood Adv 2020 Jun;4(11):2392-2403

Leicester Cancer Research Centre and.

The mutational landscape of peripheral T-cell lymphoma (PTCL) is being revealed through sequencing of lymph node samples, but there has been little work on the mutational load that is present in cell-free DNA (cfDNA) from plasma. We report targeted sequencing of cfDNA from PTCL patients to demonstrate c.50G>T (p. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2019001075DOI Listing

A Suggested Immunohistochemical Algorithm for the Classification of T Cell Lymphomas Involving Lymph Node.

Hum Pathol 2020 May 29. Epub 2020 May 29.

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

T cell lymphomas are a heterogeneous group of neoplasms derived from mature T lymphocytes. These neoplasms are uncommon and usually diagnostically challenging. The focus of this paper is to suggest an immunohistochemistry-based, practical approach to assist in the diagnosis of nodal T-cell lymphomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2020.05.006DOI Listing

Combination of multicolor flow cytometry for circulating lymphoma cells and tests for the and hot-spot mutations in plasma cell-free DNA as liquid biopsy for the diagnosis of angioimmunoblastic T-cell lymphoma.

Leuk Lymphoma 2020 May 30:1-10. Epub 2020 May 30.

Tenri Institute of Medical Research, Tenri, Japan.

We applied two-step multicolor flow cytometry (FCM) for circulating lymphoma cells in the blood of 20 patients with angioimmunoblastic T-cell lymphoma (AITL) and confirmed neoplastic T-cells in all. Eleven exhibited dim expression of CD3 and 7 lost its expression. The proportion of CD10 lymphoma cells ranged widely from 0 to 100%, with a median of 15. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2020.1768382DOI Listing

Rare non-Hodgkin lymphoma of childhood and adolescence: A consensus diagnostic and therapeutic approach to pediatric-type follicular lymphoma, marginal zone lymphoma, and nonanaplastic peripheral T-cell lymphoma.

Pediatr Blood Cancer 2020 May 26:e28416. Epub 2020 May 26.

Department of Pediatric Hematology and Oncology, The Queen Silvia's Hospital for Children and Adolescents, University of Gothenburg, Gothenburg, Sweden.

Pediatric-type follicular (PTFL), marginal zone (MZL), and peripheral T-cell lymphoma (PTCL) account each for <2% of childhood non-Hodgkin lymphoma. We present clinical and histopathological features of PTFL, MZL, and few subtypes of PTCL and provide treatment recommendations. For localized PTFL and MZL, watchful waiting after complete resection is the therapy of choice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.28416DOI Listing

T-cell and NK-cell lymphomas in the lung.

Semin Diagn Pathol 2020 May 16. Epub 2020 May 16.

Director of Hematopathology, Department of Pathology & Laboratory Medicine, Yale University School of Medicine, 310 Cedar Street, New Haven, CT, 06510, United States. Electronic address:

While the lung is frequently involved by systemic lymphoma, primary pulmonary lymphoma accounts for less than 1% of all extranodal ymphomas. In particular, T-cell lymphoma is very rare in the lung, as a primary or secondary lesion. Patients with pulmonary T-cell lymphoma usually present with cough, dyspnea, pain, fever, recurrent infections, and hemoptysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.semdp.2020.04.003DOI Listing

Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms.

Blood Adv 2020 May;4(10):2261-2271

Hematopathology Service, Department of Pathology.

TET2 and DNMT3A mutations are frequently identified in T-cell lymphomas of T follicular helper cell origin (TCL-TFH), clonal hematopoiesis (CH), and myeloid neoplasms (MNs). The relationships among these 3 entities, however, are not well understood. We performed comprehensive genomic studies on paired bone marrow and tissue samples as well as on flow cytometry-sorted bone marrow and peripheral blood subpopulations from a cohort of 22 patients with TCL-TFH to identify shared CH-type mutations in various hematopoietic cell compartments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2020001636DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252546PMC

Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

J Hematol Oncol 2020 May 19;13(1):56. Epub 2020 May 19.

Department of Hematology, Hôpital Pitié Salpêtrière, Paris, France.

Background: Peripheral T cell lymphomas form a heterogeneous group with a usually dismal prognostic. The place of allogeneic stem cell transplantation to treat PTCL is debated.

Methods: We retrospectively analyzed the overall survival (OS), event-free survival (EFS), relapse, and transplant-related mortality (TRM) and associated variables in 285 adults with non-primary cutaneous PTCL (PCTL-NOS (39%), angioimmunoblastic T cell lymphomas (29%), anaplastic T cell lymphomas (15%), and other subtypes (17%)), who received alloSCT in 34 centers between 2006 and 2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-020-00892-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236365PMC

[Clinical outcomes of hematopoietic stem cell transplantation for angioimmunoblastic T-cell lymphoma].

Zhonghua Xue Ye Xue Za Zhi 2019 Jul;40(7):573-577

Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.

To evaluate clinical outcomes of autologous (auto-HSCT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) for angioimmunoblastic T-cell lymphoma (AITL) . From June 2007 to June 2017, clinical data of AITL patients who underwent HSCT in eight hospitals were assessed retrospectively. Of 19 patients, 13 male and 6 female with a median age of 50 (32-60) years old, 12 auto-HSCT and 7 allo-HSCT recipients were enrolled in this study, all donors were HLA-identical siblings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.07.007DOI Listing

[Leucovorin Administration Allows Continued Pralatrexate Treatment in a Patient with Angioimmunoblastic T-Cell Lymphoma].

Gan To Kagaku Ryoho 2020 Jan;47(1):95-97

Dept. of Hematology, Rinku General Medical Center.

Pralatrexate(PDX)has been approved for the treatment of relapsed/refractory peripheral T-cell lymphoma(PTCL), including angioimmunoblastic T-cell lymphoma(AITL). Oral mucositis is the most common and severe adverse effect of PDX that often leads to dose reduction or omission. Herein, we report a 65-year-old man with AITL, who received PDX treatment after a second relapse. Read More

View Article

Download full-text PDF

Source
January 2020

Diagnostic Dilemma: An Unusual Case of Angioimmunoblastic T-Cell Lymphoma Manifesting as Bone Marrow Non-Caseating Granuloma.

J Hematol 2020 Apr 23;9(1-2):37-40. Epub 2020 Apr 23.

Northern Light Cancer Care, 33 Whiting Hill Road, Brewer, ME 04412, USA.

We present here a rare and unusual presentation of angioimmunoblastic T-cell lymphoma with non-necrotizing granuloma of bone marrow. We did not find any case reports of such case in our literature search. A 77-year-old man presented with shortness of breath, generalized weakness, fatigue and weight loss. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14740/jh607DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188380PMC

T-cell lymphomas in a tertiary care center of Mangalore.

J Cancer Res Ther 2020 Jan-Mar;16(1):94-97

Departments of Pathology and Oncology, Kasturba Medical College, M.A.H.E., Mangalore, Karnataka, India.

Background: The clinicomorphology and immunohistochemical features of T-cell lymphomas have been documented.

Aim: The aim of the study was to evaluate the spectrum of clincopathological features of T-cell lymphoma with immunohistochemistry correlation in a tertiary care center.

Materials And Methods: The present study was conducted on 19 biopsy specimens received from the Department of Pathology, Kasturba Medical College, from referral hospitals of Mangalore city. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jcrt.JCRT_60_17DOI Listing

Circulating angioimmunoblastic T-cell lymphoma cells.

Blood 2020 Apr;135(18):1607

Georgios Gennimatas Hospital.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020004944DOI Listing

Characterizing the belinostat response in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma.

Leuk Lymphoma 2020 Apr 26:1-5. Epub 2020 Apr 26.

Center for Lymphoid Malignancies, Columbia University Medical Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2020.1753044DOI Listing

Effects of stem cell transplantation in patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma.

Int J Hematol 2020 Apr 15. Epub 2020 Apr 15.

Department of Hematology and Clinical Research Institute, National Hospital Organization Kyushu Medical Center, 1-8-1 Jigyohama, Chuo-Ku, Fukuoka, 810-8563, Japan.

The effects of stem cell transplantation (SCT) in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL) remain controversial. We analyzed the feasibility of SCT and risk factors associated with outcomes of PTCL-NOS and AITL patients to identify the potential clinical efficacy of SCT. We retrospectively analyzed the data of PTCL-NOS (n = 83) and AITL (n = 112) patients who received autologous (n = 10 and 16, respectively) or allogeneic (n = 12 and 4, respectively) SCT, or no SCT (n = 61 and 92, respectively) between 2008 and 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-020-02879-wDOI Listing

Therapy of Peripheral T Cell Lymphoma: Focus on Nodal Subtypes.

Curr Oncol Rep 2020 Apr 16;22(5):44. Epub 2020 Apr 16.

Department of Medicine, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, 676 N. St. Clair Street, Suite 850, Chicago, IL, 60611, USA.

Purpose Of Review: Peripheral T cell lymphomas (PTCLs) are a heterogeneous group of non-Hodgkin lymphomas with inferior prognosis compared with their B cell counterparts characterized by frequent relapses, resulting in a median 5-year survival of approximately 30%. Their diverse clinicopathologic features challenge existing treatment paradigms that treat all patients uniformly. Here we review recent advances in the treatment of these diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-020-00902-1DOI Listing

Erratum to Inactivation of FOXO1 induces T follicular cell polarization and involves angioimmunoblastic T cell lymphoma.

Cancer Biol Med 2020 Feb;17(1):xx

Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.20892/j.issn.2095-3941.2019.0374DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7142832PMC
February 2020

Pralatrexate injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.

Expert Rev Hematol 2020 Apr 26:1-7. Epub 2020 Apr 26.

Hematology and Bone Marrow Transplantation, Yale University School of Medicine, New Haven, CT, USA.

: Peripheral T cell lymphomas (PTCL) are a heterogenous group of lymphoproliferative disorders which are generally not curable with conventional chemotherapy and associated with inferior outcomes. Pralatrexate is a novel folate analog, the first FDA approved drug) for the treatment of relapsed/refractory (R/R) PTCL.: This paper provides a comprehensive review of PubMed literature describing the use of pralatrexate in R/R peripheral T-cell lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2020.1756257DOI Listing

Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades.

Cancer Med 2020 Apr 12. Epub 2020 Apr 12.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Haidian District, Beijing, China.

Background: The treatment outcomes and prognosis of lymphoma are affected by various factors such as hospital types. This study was to describe the temporal trend in the survival of lymphoma in an academic center in China.

Methods: A total of 3840 consecutive patients with lymphoma diagnosed between 1996 and 2015 were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3037DOI Listing

Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorders: A Clinical, Pathologic, and Molecular Study of 60 Cases Presenting With a Single Lesion: A Multicenter Study of the French Cutaneous Lymphoma Study Group.

Am J Surg Pathol 2020 Apr 7. Epub 2020 Apr 7.

INSERM U1053 Team 3 Oncogenesis of Cutaneous Lymphomas, Bordeaux Univsersity, Bordeaux.

Primary cutaneous CD4 small/medium T-cell lymphoproliferative disorder (PCSMLPD) is a recently recognized entity in the 2017 World Health Organization (WHO) classification. It belongs to the T-follicular helper (TFH) lymphoproliferations. The clinical, pathologic, and molecular features of this localized disease are underresearched. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000001470DOI Listing

The development of T-cell malignancies in patients with pre-existing myeloproliferative neoplasms: a report of three cases.

Ecancermedicalscience 2020 17;14:1011. Epub 2020 Feb 17.

Houston Methodist Cancer Center, 6445 Main Street, Outpatient Center, 24th Floor, Houston, TX 77030, USA.

Secondary acute myeloid leukaemia complicating the natural disease course of pre-existing Philadelphia chromosome-negative myeloproliferative neoplasms (PN-MPN) is well documented and associated with treatment challenges and significant morbidity. The incidence of a T-cell malignancy developing in patients with pre-existing PN-MPN is uncommon, with one case documented in the literature. We present two cases of angioimmunoblastic T-cell lymphoma (AITL) and one case of T-cell acute lymphoblastic leukaemia (T-ALL) that developed in patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF), respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3332/ecancer.2020.1011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105335PMC
February 2020

Angioimmunoblastic T-cell Lymphoma: An Unusual Case in an Octogenarian.

Cureus 2020 Feb 11;12(2):e6956. Epub 2020 Feb 11.

Internal Medicine, Hackensack Meridian Health, Ocean Medical Center, Brick, USA.

Angioimmunoblastic T-cell lymphoma (AITL) is an unusual subtype of mature peripheral T-cell lymphoma originating from the follicular T-helper cells and is often associated with autoimmune disorders. AITL is an aggressive lymphoma, presenting with constitutional symptoms, generalized lymphadenopathy, and hepatosplenomegaly. Immunohistochemistry and biopsy are diagnostic methods. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.6956DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067515PMC
February 2020

Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified.

Virchows Arch 2020 Mar 13. Epub 2020 Mar 13.

Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.

The expression patterns of programmed cell death-1 (PD-1) and programmed cell death-ligand-1 (PD-L1) and their clinicopathological implications were investigated in peripheral T cell lymphoma (PTCL) including angioimmunoblastic T cell lymphoma (AITL) and PTCL-not otherwise specified (PTCL-NOS). PTCL-NOS was further classified into nodal PTCL with follicular helper T cell (Tfh) phenotype ("PTCL-Tfh_new") and "PTCL-NOS_new". PD-1 and PD-L1 expression on tumor cells and reactive immune cells was evaluated using immunohistochemistry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00428-020-02790-zDOI Listing

[Angioimmunoblastic T-cell lymphoma complicated with various autoimmune abnormalities and myelofibrosis].

Rinsho Ketsueki 2020 ;61(2):110-115

Department of Hematology/Oncology, University of Yamanashi.

Angioimmunoblastic T-cell lymphoma (AITL) is frequently associated with immunological abnormalities, such as hypergammaglobulinemia, autoimmune cytopenia, and the presence of various autoantibodies. Few reports on AITL have also described the development of myelofibrosis resulting from the invasion of lymphoma cells that produced various cytokines, including TGF-β. Interestingly, recent studies demonstrated that autoimmunity can directly cause autoimmune myelofibrosis (AIMF). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11406/rinketsu.61.110DOI Listing

Application of NanoString technologies in angioimmunoblastic T cell lymphoma.

Genes Genomics 2020 Apr 7;42(4):485-494. Epub 2020 Mar 7.

Department of Nanobiomedical Science and BK21 PLUS NBM Global Research Center for Regenerative Medicine, Dankook University, Cheonan, 31116, Republic of Korea.

Background: Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive disease. Most cancer diagnoses are determined by anatomical histology. Therefore, many samples are stored in FFPE blocks for H&E staining. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13258-020-00919-7DOI Listing

Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease.

BMC Res Notes 2020 Mar 7;13(1):139. Epub 2020 Mar 7.

Institute for Hematopathology, Hamburg, Germany.

Objective: Programmed death-1 (PD-1) and its ligand PD-L1 are now used as predictive biomarkers to guide clinical decisions. Precise characterization of PD-L1-positive cells may contribute to our knowledge of which patients derive benefit from the PD-L1 blockade therapy.

Results: To address this issue, we performed immunophenotyping of PD-L1-positive cells in Hodgkin lymphoma and in angioimmunoblastic T cell lymphoma (AITL) employing multiple immunofluorescent immunolabeling. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13104-020-04975-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060537PMC

Progression of AITL-like tumors in mice is driven by Tfh signature proteins and T-B cross talk.

Blood Adv 2020 Mar;4(5):868-879

Institut de Recherches Cliniques de Montréal (IRCM), Montréal, QC, Canada.

Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive peripheral T-cell lymphoma driven by a pool of neoplastic cells originating from T follicular helper (Tfh) cells and concomitant expansion of B cells. Conventional chemotherapies for AITL have shown limited efficacy, and as such, there is a need for improved therapeutic options. Because AITL originates from Tfh cells, we hypothesized that AITL tumors continue to rely on essential Tfh components and intimate T-cell-B-cell (T-B) interactions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2019001114DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065475PMC

Case Report: Pure Red Cell Aplasia due to Angioimmunoblastic T-Cell Lymphoma.

Case Rep Oncol 2020 Jan-Apr;13(1):76-78. Epub 2020 Feb 6.

Department of Internal Medicine, Hospital Professor Doutor Fernando Fonseca, Amadora, Portugal.

Pure red cell aplasia (PRCA) is a rare bone marrow failure characterized by a progressive normocytic anemia and reticulocytopenia without leukopenia and thrombocytopenia. It can be associated with various hematological disorders but exceedingly rarely with angioimmunoblastic T-cell lymphoma (AITL). We report the case of a 72-year-old woman with PRCA associated with AITL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000505533DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036571PMC
February 2020

Dasatinib Is an Effective Treatment for Angioimmunoblastic T-cell Lymphoma.

Cancer Res 2020 May 27;80(9):1875-1884. Epub 2020 Feb 27.

Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.

Recurrent hotspot (p.Gly17Val) mutations in encoding a small GTPase, together with loss-of-function mutations in encoding an epigenetic regulator, are genetic hallmarks of angioimmunoblastic T-cell lymphoma (AITL). Mice expressing the p. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-19-2787DOI Listing

High-mobility group box (TOX) antibody a useful tool for the identification of B and T cell subpopulations.

PLoS One 2020 27;15(2):e0229743. Epub 2020 Feb 27.

Monoclonal Antibodies Core Unit, CNIO, Madrid, Spain.

Thymocyte selection-associated high-mobility group box (TOX) is a DNA-binding factor that is able to regulate transcription by modifying local chromatin structure and modulating the formation of multi-protein complexes. TOX has multiple roles in the development of the adaptive immune system including development of CD4 T cells, NK cells and lymph node organogenesis. However very few antibodies recognizing this molecule have been reported and no extensive study of the expression of TOX in reactive and neoplastic lymphoid tissue has been performed to date. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0229743PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046285PMC
May 2020
3.234 Impact Factor

The derived neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with angioimmunoblastic T-cell lymphoma.

Br J Haematol 2020 Feb 27. Epub 2020 Feb 27.

Department of Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.

To determine whether inflammatory markers, derived neutrophil-to-lymphocyte ratio (dNLR), haemoglobin/platelet ratio (HPR) or platelet/lymphocyte ratio (PLR) are predictive for prognosis in angioimmunoblastic T-cell lymphoma (AITL), we derived dNLR, HPR and PLR values for 110 AITL patients and appropriate cut-off point values to define overall survival (OS) and progression-free survival (PFS). dNLR ≥ 2·2, HPR ≥ 0·4 or PLR < 100 were significant factors for shorter OS and PFS. On univariate analysis, these three parameters were significantly associated with worse OS and PFS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16447DOI Listing
February 2020

The efficacy and safety of Epstein-Barr virus-specific antigen peptide-activated cytotoxic T-cells treatment for refractory or recurrent angioimmunoblastic T-cell lymphoma: A prospective clinical observational study.

Hematol Oncol 2020 Feb 21. Epub 2020 Feb 21.

Department of Hematology, Peking University First Hospital, Beijing, China.

The efficacy and safety of Epstein-Barr virus (EBV)-specific antigen peptide-activated cytotoxic T lymphocytes (CTLs) in the treatment of refractory or recurrent angioimmunoblastic T-cell lymphoma (AITL) was determined in this prospective one-arm clinical study. Seven males and two females were enrolled with a median age of 70 years. The tumor stages were all stage III and IV. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2726DOI Listing
February 2020
3.084 Impact Factor

RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group.

Ann Hematol 2020 Apr 20;99(4):799-808. Epub 2020 Feb 20.

Haematology Department, Hospital Clinic of Barcelona, Barcelona, Cataluña, Spain.

Lymphomas are a large, heterogeneous group of neoplasms with well-defined characteristics, and this heterogeneity highlights the importance of epidemiological data. Knowledge of local epidemiology is essential to optimise resources, design clinical trials, and identify minority entities. Given there are few published epidemiological data on lymphoma in Spain, the Spanish Lymphoma and Autologous Bone Marrow Transplant Group created the RELINF project. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-03918-6DOI Listing

The new biology of PTCL-NOS and AITL: current status and future clinical impact.

Br J Haematol 2020 Apr 17;189(1):54-66. Epub 2020 Feb 17.

Leicester Cancer Research Centre, Ernest and Helen Scott Haematology Research Institute, University of Leicester, Leicester, UK.

Peripheral T-cell lymphomas (PTCL) comprise a heterogeneous group of aggressive lymphoproliferative disorders almost all of which are associated with poor clinical outcomes. Angioimmunoblastic T-cell lymphoma (AITL) and some peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) have similarities to normal CD4 T-cell subsets in their gene expression profiles. A cell of origin model is, therefore, emerging and is likely to be refined in the future. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16428DOI Listing

Relapsed angioimmunoblastic T-cell lymphoma with large pericardial effusion.

Proc (Bayl Univ Med Cent) 2020 Jan 25;33(1):62-64. Epub 2019 Oct 25.

Department of Internal Medicine, Baylor University Medical CenterDallasTexas.

T-cell lymphomas comprise 10% to 15% of all lymphoid malignancies and affect precursor or mature T cells; the latter are referred to as peripheral T-cell lymphomas. We present a case of a subtype, angioimmunoblastic T-cell lymphoma, in which a patient previously treated with chemotherapy and autologous stem cell transplant relapsed with B symptoms and large pericardial/pleural effusions. Recurrent lymphoma was confirmed on pericardial tissue biopsy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/08998280.2019.1668720DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988641PMC
January 2020

Discordant lymphoma consisting of mantle cell lymphoma and angioimmunoblastic T cell lymphoma: homology or heterogeneity?

Int J Clin Exp Pathol 2020 1;13(1):73-80. Epub 2020 Jan 1.

Department of Pathology, Affiliated Yantai Yuhuangding Hospital, Qingdao University 20 Yuhuangding East Road, Yantai 264000, China.

Objects: To investigate the pathologic characteristic of discordant lymphoma with mantle cell lymphoma and angioimmunoblastic T cell lymphoma.

Methods: The clinicopathologic data of cases of discordant lymphoma were organized and clinicopathologic features were analyzed by literature review.

Results: A 49-year-old male was taken to the hospital due to the lymphandenopathy in January 2007 and mantle cell lymphoma was diagnosed in the pathology report. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7013375PMC
January 2020
1.783 Impact Factor

Clinical analysis of 20 patients with non-Hodgkin lymphoma and autoimmune hemolytic anemia: A retrospective study.

Medicine (Baltimore) 2020 Feb;99(7):e19015

Non-Hodgkin lymphoma (NHL) can co-exist with autoimmune hemolytic anemia (AIHA), a phenomenon known as AIHA-associated NHL (AIHA/NHL). However, few studies have reported AIHA/NHL incidence or its clinical characteristics. We conducted a retrospective analysis of 20 AIHA/NHL patients treated at our hospital from 2009 to 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000019015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035012PMC
February 2020

Hypereosinophilia with angioimmunoblastic T-cell lymphoma.

Ann Allergy Asthma Immunol 2020 05 8;124(5):513-515. Epub 2020 Feb 8.

Department of Allergy and Immunology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anai.2020.01.028DOI Listing

Leukaemic relapse of angioimmunoblastic T-cell lymphoma.

Br J Haematol 2020 May 9;189(4):592. Epub 2020 Feb 9.

Department of Haematology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16475DOI Listing

Non-mycosis fungoides cutaneous lymphomas in a referral center in Taiwan: A retrospective case series and literature review.

PLoS One 2020 24;15(1):e0228046. Epub 2020 Jan 24.

Department of Dermatology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.

Background: While mycosis fungoides (MF) and Sézary syndrome (SS) are the most common cutaneous lymphomas (CLs), there is limited data about non-MF/SS CLs.

Objective: We aimed to evaluate clinical characteristics of non-MF/SS CLs.

Methods: A retrospective analysis evaluated patients with non-MF/SS CLs covering a period of 17 years. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0228046PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6980583PMC

Inactivation of FOXO1 induces T follicular cell polarization and involves angioimmunoblastic T cell lymphoma.

Cancer Biol Med 2019 Nov;16(4):743-755

Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.

Objective: Angioimmunoblastic T cell lymphoma (AITL) is an aggressive form of non-Hodgkin lymphoma derived from mature T cells. However, the underlying pathogenesis of AITL remains unresolved. We aimed to explore the role of FOXO1-mediated signaling in the tumorigenesis and progression of AITL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.20892/j.issn.2095-3941.2019.0115DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936234PMC
November 2019

Targeting epigenetic regulators in the treatment of T-cell lymphoma.

Expert Rev Hematol 2020 Feb 22;13(2):127-139. Epub 2020 Jan 22.

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

: T-cell lymphomas represent a broad group of malignant T-cell neoplasms with marked molecular, clinical, and biologic heterogeneity. Survival rates after conventional chemotherapy regimens are poor for most subtypes and new therapies are needed. Rapidly expanding knowledge in the field of epigenomics and the development of an increasing number of epigenetic-modifying agents have created new opportunities for epigenetic therapies for patients with this complex group of diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2020.1711732DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110907PMC
February 2020

[VEGF secretion from Epstein-Barr virus-infected cells as a cause of severe anasarca in a patient with angioimmunoblastic T-cell lymphoma].

Rinsho Ketsueki 2019 ;60(12):1647-1651

Division of Hematology, National Defense Medical College Hospital.

A 69-year-old woman presented to National Defense Medical College hospital for suspected nephrotic syndrome due to weight gain of 30 kg in 3 weeks and bilateral lower leg edema. However, her urinalysis showed microproteinuria, which excluded nephrotic syndrome. Computed tomography revealed severe systemic edema, pleural effusion, ascites, and enlarged cervical and axillary lymph nodes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11406/rinketsu.60.1647DOI Listing
January 2020

High expression levels of TLR9 and PD-L1 indicates a poor prognosis in patients with angioimmunoblastic T-cell lymphoma: a retrospective study of 88 cases in a single center.

J Cancer 2020 1;11(1):57-68. Epub 2020 Jan 1.

Department of Clinical Laboratory, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081, P. R. China.

The role of TLR9 expressed by tumor cells in evading immune surveillance was confirmed. PD-L1 expression in tumor cells plays a key role in tumor immune escape, which is associated with poor prognosis. However, the clinical relevance of TLR9 and PD-L1 expression in angioimmunoblastic T-cell lymphoma (AITL) has not been evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/jca.37033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930404PMC
January 2020

Epstein-Barr virus infection or malignant lymphoma - what you see is not what you get.

Neth J Med 2019 12;77(10):370-372

Department of Haematology, Erasmus Medical Centre Cancer Institute, Rotterdam, the Netherlands.

Infectious mononucleosis may mimic lymphoma, both clinically and histopathologically. We present a patient with neurological symptoms and lymphadenopathy, initially diagnosed as Epstein-Barr virus (EBV)-positive angioimmunoblastic T-cell lymphoma (AITL) with cerebrospinal fluid (CSF) localisation based on lymph node pathology and a 30-fold higher EBV load in the CSF compared with serum. However, the patient fully recovered spontaneously and EBV became negative in both CSF and serum, suggestive of a dramatic presentation of EBV meningoencephalitis. Read More

View Article

Download full-text PDF

Source
December 2019

Update on peripheral T-cell lymphomas with T-helper phenotype:  Are there too many subtypes?

Semin Diagn Pathol 2020 Jan 17;37(1):24-31. Epub 2019 Dec 17.

Servicio de Anatomía Patológica, Fundación Jiménez Díaz, CIBERONC, Madrid, Spain.

Follicular helper T (T) cells are the providers of T-cell help to B-cells in the development of germinal centers and for the generation of most class-switched antibodies. The markers most commonly associated with T activity are IL21, IL4, CD40L, BCL6, SAP, CXCR5/CXCL13, and ICOS. T-cell lymphoma genomic studies have shown that different T-cell lymphoma types express signatures typical for T cells, this including angioimmunoblastic T-cell lymphoma (AITL), a related condition termed peripheral T-cell lymphoma with T phenotype and primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.semdp.2019.12.005DOI Listing
January 2020

Angioimmunoblastic T-cell lymphoma in Taiwan reveals worse progression-free survival for G17V mutated subtype.

Leuk Lymphoma 2020 May 23;61(5):1108-1118. Epub 2019 Dec 23.

Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

Angioimmunoblastic T-cell lymphoma (AITL) carries genetic mutations of , , and , but the prognostic impact of these mutations is not widely investigated. Although one study shows no difference in overall survival between patients with or without G17V mutation, a poor performance status is associated with G17V-mutated AITL, which is an independent adverse factor. We retrospectively investigated the prognostic impact of G17V mutation in AITL patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1702179DOI Listing

Angioimmunoblastic T-cell lymphoma contains multiple clonal T-cell populations derived from a common TET2 mutant progenitor cell.

J Pathol 2020 Mar 16;250(3):346-357. Epub 2020 Jan 16.

Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK.

Angioimmunoblastic T-cell lymphoma (AITL) is a neoplastic proliferation of T follicular helper cells with clinical and histological presentations suggesting a role of antigenic drive in its development. Genetically, it is characterized by a stepwise acquisition of somatic mutations, with early mutations involving epigenetic regulators (TET2, DNMT3A) and occurring in haematopoietic stem cells, with subsequent changes involving signaling molecules (RHOA, VAV1, PLCG1, CD28) critical for T-cell biology. To search for evidence of potential oncogenic cooperation between genetic changes and intrinsic T cell receptor (TCR) signaling, we investigated somatic mutations and T-cell receptor β (TRB) rearrangement in 119 AITL, 11 peripheral T-cell lymphomas with T follicular helper phenotype (PTCL-TFH), and 25 PTCL-NOS using Fluidigm polymerase chain reaction (PCR) and Illumina MiSeq sequencing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/path.5376DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064999PMC

EBV status has prognostic implication among young patients with angioimmunoblastic T-cell lymphoma.

Cancer Med 2020 Jan 2;9(2):678-688. Epub 2019 Dec 2.

Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan.

Epstein-Barr virus (EBV)-positive B cells have been detected in 66%-86% of patients with angioimmunoblastic T-cell lymphoma (AITL). However, it remains controversial whether EBV status has an impact on the survival of patients with AITL. In this study, we aimed to reevaluate the impact of EBV on the clinicopathological characteristics of AITL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.2742DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6970042PMC
January 2020

Approach to nodal-based T-cell lymphomas.

Pathology 2020 Jan 28;52(1):78-99. Epub 2019 Nov 28.

Institute of Pathology, Lausanne University Hospital (CHUV) and Lausanne University, Lausanne, Switzerland. Electronic address:

Peripheral T-cell lymphomas (PTCLs) represent a heterogeneous group of uncommon malignancies derived from mature T cells and usually characterised by an aggressive clinical course. Their clinical presentation, localisation and pattern of dissemination are highly variable, but the majority of cases present as nodal diseases. The recently revised classification of lymphomas has incorporated many new molecular genetic data derived from gene expression profiling and next generation sequencing studies, which refine the definition and diagnostic criteria of several entities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pathol.2019.09.012DOI Listing
January 2020